Search
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalHyperforin is a phytochemical generated by the plants of the Hypericum family.
Sea salt
go.drugbank.com/drugs/DB11266ApprovedSea salt is a food ingredient and is often colored by adding charcoal or red clay to sometimes be referred to as “Hawaiian Sea Salt.”
Synonyms: bay saltDordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigationalOn August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.
PBI-1402
go.drugbank.com/drugs/DB05480ExperimentalPBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.
LX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia
Melanoma antigen recognized by T-cells 1
go.drugbank.com/drugs/DB15081InvestigationalMelanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Synonyms: Melanoma antigen recognized by T-cells 1Pipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnPipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...
PW2101
go.drugbank.com/drugs/DB06483ExperimentalThe drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.
VE303
go.drugbank.com/drugs/DB17794InvestigationalVE303 is under clinical development by Vedanta Biosciences.